Viridian Therapeutics, Inc.
VRDN
$28.68
$0.270.95%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -99.81% | 93,993.33% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -99.81% | 93,993.33% | |||
| Cost of Revenue | 7.47% | -0.42% | |||
| Gross Profit | -489.99% | 81.87% | |||
| SG&A Expenses | 38.45% | 20.31% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.29% | 3.50% | |||
| Operating Income | -215.52% | 62.52% | |||
| Income Before Tax | -247.86% | 65.65% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -247.86% | 65.65% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -247.86% | 65.65% | |||
| EBIT | -215.52% | 62.52% | |||
| EBITDA | -216.09% | 62.59% | |||
| EPS Basic | -210.95% | 65.72% | |||
| Normalized Basic EPS | -210.21% | 65.73% | |||
| EPS Diluted | -210.95% | 65.72% | |||
| Normalized Diluted EPS | -210.21% | 65.73% | |||
| Average Basic Shares Outstanding | 15.40% | 0.23% | |||
| Average Diluted Shares Outstanding | 15.40% | 0.23% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||